Eli Lilly and Co. says it will delay most new study starts and pause enrollment in most ongoing studies, due to the impact of the COVID-19 pandemic. Lilly is continuing ongoing clinical trials for patients who are already enrolled. The COVID-19 pandemic has substantially impacted the global healthcare delivery system, including the conduct of clinical trials. Many healthcare systems have had to restructure operations to prioritize caring for COVID-19 patients and limiting or ceasing other act...